- ¥1880 - 2880
- 百奥莱博
- JN0568-WQT
- 北京
- 2025年07月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
222
- 英文名：
Recombinant Human Low Affinity Immunoglobulin Gamma Fc Region Receptor II-B
- 保质期：
长期
- 供应商：
北京百奥莱博科技有限公司
- 保存条件：
冻干蛋白置于-20℃
- 规格：
10μg|50μg|500μg|1mg
特别提示：包括重组人FcγRIIB在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！
产品名称：重组人FcγRIIB
英文名称：Recombinant Human Low Affinity Immunoglobulin Gamma Fc Region Receptor II-B
产品货号：JN0568
产品规格：10μg|50μg|500μg|1mg
本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Thr43-Pro217在C端含有His标签。
FcγRIIB质量控制：＞95%(还原性SDS-PAGE)
FcγRIIB制剂：冻干品
FcγRIIB保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。
FcγRIIB复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。
关于FcγRIIB：
FcγRIIB is a low affinity receptor that recognizes the Fc portion of IgG. The human CD32 group consists of FcγRIIA, FcγRIIB, and FcγRIIC proteins that share 94-99% sequence identity in their extracellular domains but differ substantially in their transmembrane and cytoplasmic domains. FcγRII protein is expressed on cells of both myeloid and lymphoid lineages as well as on cells of non-hematopoietic origin. FcγRIIB has an intrinsic cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) and delivers an inhibitory signal upon ligand binding. Ligation of FcγRIIB on B cells down-regulates antibody production and in some circumstances may promote apoptosis. Co-ligation of FcγRIIB on dendritic cells inhibits maturation and blocks cell activation. FcγRIIB may also be a target for monoclonal antibody therapy for malignancies. FcγRIIB plays an important negative-regulating role through modulating the signals from activation receptors.
我公司销售的重组人FcγRIIB报价，重组Low Affinity Immunoglobulin Gamma Fc Region Receptor II-B，Recombinant Human Low Affinity Immunoglobulin Gamma Fc Region Receptor II-B，重组人Low Affinity Immunoglobulin Gamma Fc Region Receptor II-B质量上佳，价格普惠，欢迎广大新老客户踊跃订购。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Induction of Tolerogenic Dendritic Cells by NF-B Blockade and Fc Receptor Modulation
and in vivo , that NF-κB blockade on DCs by andrographolide or rosiglitazone can significantly enhance the tolerogenic capacity of DCs. Furthermore, we have observed that expression ratio of the activating FcγRIII or the inhibitory FcγRIIb is determinant
APCS（SAP）分子特征、免疫调控机制与相关疾病及靶向治疗进展
γR与抑制型FcγRIIB（携带ITIM基序）之间的信号平衡，从而精确调控免疫应答。 APCS的功能 SAP（血清淀粉样蛋白P成分）是一种多功能免疫调节蛋白，它以钙依赖的方式与DNA、染色体及凋亡碎片等配体结合，协助机体清除细胞死亡或组织损伤后产生的物质。此外，SAP还能结合高密度脂蛋白（HDL）和极低密度脂蛋白，提示其参与脂蛋白代谢。通过与补体系统及FcγR（如FcγRI/III）相互作用，SAP在免疫调控中发挥关键作用：它能减少中性粒细胞黏附，调节巨噬细胞的活化与极化，增强对细胞碎片的吞噬
Novel Opportunities for Therapeutic Targeting in Systemic Autoimmune Diseases
) antagonists, and FcγRIIB receptor antagonists. Also promising is the current interest centered on the development of inhibition of signal transduction pathways, such as pharmacological inhibitors that act at various levels of signal transduction pathways.
技术资料暂无技术资料 索取技术资料
